Price T Rowe Associates Inc. MD Has $59,000 Stock Holdings in Gossamer Bio, Inc. (NASDAQ:GOSS)

Price T Rowe Associates Inc. MD trimmed its position in shares of Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) by 99.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 64,777 shares of the company's stock after selling 6,369,269 shares during the quarter. Price T Rowe Associates Inc. MD's holdings in Gossamer Bio were worth $59,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GOSS. Monaco Asset Management SAM boosted its position in shares of Gossamer Bio by 39.5% during the fourth quarter. Monaco Asset Management SAM now owns 5,371,641 shares of the company's stock worth $4,859,000 after purchasing an additional 1,520,721 shares in the last quarter. Silverarc Capital Management LLC lifted its position in Gossamer Bio by 9.3% in the 4th quarter. Silverarc Capital Management LLC now owns 6,171,847 shares of the company's stock valued at $5,583,000 after acquiring an additional 526,495 shares in the last quarter. Smith Moore & CO. lifted its position in Gossamer Bio by 32.7% in the 4th quarter. Smith Moore & CO. now owns 300,000 shares of the company's stock valued at $271,000 after acquiring an additional 74,000 shares in the last quarter. Geode Capital Management LLC lifted its position in Gossamer Bio by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 2,250,461 shares of the company's stock valued at $2,037,000 after acquiring an additional 38,084 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Gossamer Bio by 1.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company's stock valued at $1,123,000 after acquiring an additional 13,902 shares in the last quarter. 81.23% of the stock is owned by institutional investors.

Gossamer Bio Trading Down 1.0%

Shares of NASDAQ:GOSS opened at $1.04 on Monday. The company's 50-day moving average price is $1.04 and its two-hundred day moving average price is $0.99. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. Gossamer Bio, Inc. has a one year low of $0.50 and a one year high of $1.55. The stock has a market capitalization of $236.31 million, a PE ratio of -3.25 and a beta of 1.82.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.02. The business had revenue of $9.89 million for the quarter, compared to the consensus estimate of $3.95 million. On average, equities analysts forecast that Gossamer Bio, Inc. will post -0.28 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on GOSS. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Gossamer Bio in a research report on Tuesday, March 18th. The Goldman Sachs Group boosted their price objective on shares of Gossamer Bio from $7.00 to $8.00 and gave the company a "buy" rating in a research report on Friday. Finally, Wedbush reaffirmed an "outperform" rating and issued a $4.00 price objective on shares of Gossamer Bio in a research report on Friday.

Gossamer Bio Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.